Leukemia News and Research

RSS
Leukemia (Leukaemia) is a cancer of the blood cells. It is the most common type of blood cancer and affects 10 times as many adults as children. Most people diagnosed with leukemia are over 50 years old. No one knows why some people develop leukemia and others do not. However, scientists have identified some risk factors for the disease. Most people who have known risk factors do not get leukemia, while many who do get the disease have none of these risk factors. During the early stages of leukemia, there may be no symptoms. Many of the symptoms of leukemia don't become apparent until a large number of normal blood cells are crowded out by leukemia cells.
Two gene alterations pair up to promote growth of leukemia cells

Two gene alterations pair up to promote growth of leukemia cells

Kiadis Pharma signs Services Agreement with GRCBDS for Phase II clinical study with ATIR

Kiadis Pharma signs Services Agreement with GRCBDS for Phase II clinical study with ATIR

Researchers identify protein that triggers inflammation in patients with hemorrhage, sepsis

Researchers identify protein that triggers inflammation in patients with hemorrhage, sepsis

New therapeutic targets and drugs may benefit people with leukemia

New therapeutic targets and drugs may benefit people with leukemia

Active ingredient of ipecac syrup inhibits growth of cancer cells

Active ingredient of ipecac syrup inhibits growth of cancer cells

NYU researchers receive $6.25M grant for pioneering research into acute lymphoblastic leukemia

NYU researchers receive $6.25M grant for pioneering research into acute lymphoblastic leukemia

Research reveals significant role of Axl receptor in progression, therapeutic resistance of AML

Research reveals significant role of Axl receptor in progression, therapeutic resistance of AML

Standoff between a mutated gene and normal counterpart keeps certain cancer cells alive

Standoff between a mutated gene and normal counterpart keeps certain cancer cells alive

MD Anderson-developed aerosol triggers innate immunity to squelch infections

MD Anderson-developed aerosol triggers innate immunity to squelch infections

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

FDA approves Cimzia (certolizumab pegol) for active psoriatic arthritis

BioLineRx announces regulatory submissions to commence Phase 1/2 trial for treatment of celiac disease

BioLineRx announces regulatory submissions to commence Phase 1/2 trial for treatment of celiac disease

Researchers discover drug that halts growth of brain tumor cells

Researchers discover drug that halts growth of brain tumor cells

Study sheds new light on the dark matter of genome

Study sheds new light on the dark matter of genome

Researchers discover why multiple myeloma recurs after initially effective treatment

Researchers discover why multiple myeloma recurs after initially effective treatment

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

FDA grants Breakthrough Therapy designation to Boehringer Ingelheim's volasertib

Inside Jersey magazine names Rutgers Cancer Institute of New Jersey physicians among Top Doctors

Inside Jersey magazine names Rutgers Cancer Institute of New Jersey physicians among Top Doctors

Immune marker predicts transplant success, improves selection of bone marrow donors

Immune marker predicts transplant success, improves selection of bone marrow donors

TSRI scientists find new way to boost effectiveness of anticancer drugs

TSRI scientists find new way to boost effectiveness of anticancer drugs

Young people remain in the dark as Obamacare exchanges prepare to open

Young people remain in the dark as Obamacare exchanges prepare to open

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

Affimed Therapeutics, LLS partner to co-fund AFM13 phase 2 trial for treatment of Hodgkin Lymphoma

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.